• The companies are using a proprietary technology to track specific conversations regarding COVID-19
• The transaction marks W2O’s fifth purchase in nine months with Symplur now operating under the name of W2O Symplur

W2O- a California based marketing firm and a prominent independent supplier of analytics-based, digital marketing communications to the healthcare industry, recently announced the purchase of Symplur- a social media based analytics firm that primarily focuses on the medical sector.

Reportedly, Symplur offers a simplified interface and analytical capabilities that will assist in making the data and analytics operating system and technology of W20 accessible to a wider range of non-technical users.

Apparently, W2O aims at adding new features and products to its portfolio in the near future that will benefit a wide range of healthcare clients.

Notably, the patented social media based analytics technology developed by Symplur facilitates easy and rapid identification of social media trends among patient advocates, physicians, media, life sciences professionals and other target audiences of interest to healthcare organizations, educational institutions, and government entities.  

For the record, through a partnership with the California Life Sciences Association, both Symplur and W2O are using the solution, along with the proprietary data and technology provided by W2O, to track conversations and related trends that are coronavirus specific across the healthcare system.

According to Jim Weiss, Founder and CEO, W2O, due to the recent COVID-19 pandemic, many leading healthcare companies are aiming at urgently tracking essential information with the help of data and analytics to recognize insights for decision making.

Weiss further states that Symplur‘s novel technology helps in understanding the dynamics of the complex healthcare sector and aims at strengthening the solutions that are provided to the clients. W2O comprises of various people that focus on data science, audience analytics, technology, and measurement.

Citing reliable sources, the acquisition focuses on expanding the proprietary data and technology offered by W2O, allowing the company to focus on integrating data-rich intelligence with technology to address issues related to their clients in real-time.

Seemingly, the technology and intelligence reports by Symplur are currently adopted by major pharmaceutical entities and government agencies, like the National Institute of Allergy and Infectious Disease and National Institutes of Health.

Source Credits: https://www.w2ogroup.com/w2o-acquires-symplur-to-innovate-scale-and-increase-accessibility-to-its-proprietary-healthcare-data-and-insights-platform/